Oxycodone 30 mg (Faroxy) Immediate-Release (IR)

Oxycodone Immediate-Release (IR) 30 mg is a potent opioid analgesic used primarily for the management of severe pain. This formulation is particularly beneficial for patients who require rapid pain relief, such as those experiencing acute pain following surgery or injury. Below is a detailed overview of the product, its indications, pharmacokinetics, and safety considerations.

Product Description

Oxycodone IR 30 mg tablets contain oxycodone hydrochloride, a white, crystalline powder that is highly soluble in water. Each tablet provides immediate analgesic effects, making it suitable for patients who need quick relief from severe pain. The immediate-release formulation allows for flexibility in dosing, enabling healthcare providers to tailor treatment based on individual patient needs.

Oxycodone 30 mg: Indications

Oxycodone IR 30 mg is indicated for:

• Management of Severe Pain: Healthcare providers primarily prescribe it for patients experiencing severe acute pain that requires an opioid analgesic.
• Postoperative Pain Relief: Healthcare providers often utilize this formulation in postoperative settings where rapid pain control is essential.
• Cancer Pain Management: Oxycodone IR can be part of a comprehensive pain management plan for patients with cancer.

Dosage and Administration

Healthcare providers should individualize the dosing of Oxycodone IR 30 mg (Faroxy) based on the severity of pain and the patient’s previous history with opioid analgesics. The typical starting dose may range from 5 mg to 15 mg every 4 to 6 hours as needed for pain. Healthcare providers should closely monitor patients to titrate the dose effectively and minimize the risk of adverse effects.

Oxycodone 30 mg: Pharmacokinetics

Oxycodone IR has a relatively rapid onset of action, with peak plasma concentrations typically reached within one hour of administration. The bioavailability of oral oxycodone varies but generally ranges from 60% to 87%. This means that a significant portion of the drug reaches systemic circulation after oral administration.

The elimination half-life of oxycodone is approximately 3 to 4 hours, which supports the need for frequent dosing in some patients. Due to its pharmacokinetic profile, oxycodone IR is particularly effective for managing breakthrough pain in patients already on long-acting opioids.

Pluvia Endo produces oxycodone hydrochloride, the active ingredient, and finished dosages in various formulations:

• Oxycodone Immediate-Release (IR) 5 mg
• Oxycodone 15 mg Immediate-Release
• Oxycodone Immediate-Release (IR) 30 mg

In addition, our products contain ER oxycodone as well as IR ones. Our ER category contains:

• Oxycodone Extended-Release (ER) 10 mg
• Oxycodone Extended-Release (ER) 20mg
• Oxycodone Extended-Release (ER) 40mg

Safety and Precautions

As with all opioid medications, Oxycodone IR carries risks of addiction, abuse, and misuse. Therefore, it is essential to implement a comprehensive treatment strategy that includes discussions about the risks and benefits of opioid therapy. Key safety considerations include:

• Respiratory Depression: Oxycodone 30 mg (Faroxy) can cause significant respiratory depression, especially in opioid-naïve patients or when combined with other CNS depressants.
• Dependence and Withdrawal: Patients should not abruptly discontinue oxycodone without consulting their healthcare provider due to the risk of withdrawal symptoms.
• Contraindications: Healthcare providers should not use oxycodone IR in patients with severe respiratory issues, acute asthma, or known hypersensitivity to opioids.

PluviaEndo: Manufacturing Excellence

Pluvia Endo commits to delivering unique quality products at competitive prices. By controlling the entire manufacturing process—from formulation to final product—the company ensures reliability. This approach allows it to provide dependable support in documentation and scientific matters for its clients. This comprehensive approach enables Pluvia Endo to meet the complex challenges faced by healthcare providers in the pharmaceutical industry.

Pluvia Endo is a multinational pharmaceutical company headquartered in Istanbul, Turkey. The company enhances healthcare through innovative solutions. It commits to producing high-quality medications across various therapeutic categories, particularly in opioid medications and nutraceutical supplements. Established with a focus on developing unique molecules and leveraging specialized know-how, Pluvia Endo has built a diverse portfolio. This portfolio includes various therapeutic categories, particularly in the fields of opioid medications and nutraceutical supplements.